Melanin, Pigment Conditions, and Suspicious-Lesion Referral

Biology of Cutaneous Melanogenesis

Melanin synthesis provides the skin's primary physiological photoprotective defense against solar ultraviolet radiation (UVR). In advanced master esthetics, understanding melanogenesis is crucial for managing hyperpigmentation, predicting responses across Fitzpatrick phototypes, and preventing post-inflammatory complications.

The Enzymatic Pathway of Melanin Synthesis

Melanocytes are specialized, dendritic, neural crest-derived cells located in the stratum basale of the epidermis, distributed among keratinocytes in a ratio of approximately 1 melanocyte to 10–36 keratinocytes (the epidermal-melanin unit).

• The Rate-Limiting Enzyme: Melanogenesis takes place within membrane-bound organelles called melanosomes, governed by the copper-dependent enzyme tyrosinase.
• The Cascade:
  1. Tyrosinase converts L-tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine).
  2. Tyrosinase oxidizes L-DOPA to dopaquinone.
  3. Divergence:
     • Eumelanin Pathway: Dopaquinone cyclizes into dopachrome, forming DHI and DHICA, which polymerize into eumelanin—an insoluble brown-black pigment that absorbs UV, dissipates heat, and scavenges free radicals.
     • Pheomelanin Pathway: In the presence of cysteine, dopaquinone binds cysteine to form cysteinyl-DOPA, polymerizing into pheomelanin—a yellow-red pigment that offers poor photoprotection and generates reactive oxygen species (ROS) upon UV exposure.
• Melanosome Transfer: Melanosomes mature (Stages I–IV) and reach keratinocytes through transfer processes that remain under investigation, including uptake of pigment material, forming a supranuclear "cap" shielding nuclear DNA from UV damage.

Pigment patterns and limitations of observation

Hyperpigmentation means increased visible pigment; hypopigmentation means reduced pigment. Post-inflammatory hyperpigmentation can follow irritation or injury, including cosmetic procedures. It can occur across skin tones, though susceptibility and persistence vary. Avoid producing inflammation in order to treat a color change aggressively.

Melasma is a medical pigment condition with multiple influences. Lentigines, freckles, and other pigmented findings have different clinical contexts. An esthetician should not assume every brown spot is one of them or remove a spot before it is assessed. New, changing, asymmetrical, or bleeding pigment is a referral concern.

Vitiligo and albinism are distinct conditions. Albinism includes heterogeneous inherited disorders affecting melanin production; it is not universally complete absence of tyrosinase in every person. Reduced pigmentation can also arise after injury or disease. Record the actual history and medical diagnosis if available rather than classifying every pale patch as vitiligo.

Wood's-lamp findings can support aspects of clinical examination under appropriate conditions, but do not prove pigment depth in every skin tone or formulation. Cosmetics and other substances can affect fluorescence. Do not select a deeper peel merely because a spot does not appear to enhance under a lamp.

Prescription pigment treatment belongs to an authorized prescriber. Hydroquinone-containing skin-lightening products are not approved for OTC sale in the United States; do not recommend an unapproved OTC hydroquinone product as mandatory priming. Suitable cosmetic ingredients and sun protection must still fit the client's actual condition and routine.

Recognize the need for medical evaluation

Actinic keratoses are medically assessed sun-related lesions with potential significance. Basal-cell carcinoma, squamous-cell carcinoma, and melanoma have different origins and appearances, and no cosmetic checklist reliably rules them out. Do not use one universal percentage to predict progression of every actinic lesion.

A nonhealing, recurrently crusted, changing, bleeding, or unusual spot should be referred. Avoid exfoliating, extracting, freezing, or applying a laser to an undiagnosed lesion. Such treatment can injure tissue and delay or obscure diagnosis. It is inaccurate to say that peeling necessarily pushes malignant cells deeper into skin.

ABCDE, change, and the ugly-duckling concept

ABCDE is a public recognition aid: asymmetry, irregular border, varied color, diameter, and evolution. A diameter over six millimeters can be concerning, but melanoma can be smaller. Evolution includes change in size, shape, color, symptoms, or behavior. A spot unlike the person's others is sometimes described as an ugly duckling.

These are warning prompts, not definitive diagnostic criteria. Some cancers do not follow a simple visual pattern. The absence of every ABCDE feature does not certify a lesion as safe for treatment. Ask about change and prior evaluation, record observations, and recommend medical assessment when concerned.

Sun protection includes appropriate broad-spectrum sunscreen, shade, clothing, and avoiding deliberate tanning. Pigmented skin can still burn and develop skin cancer. Cosmetic tone-evening should not distract from a changing lesion or imply that sunscreen removes all risk.

A client asks to peel a dark spot that has grown and begun bleeding. Defer treatment of the spot and recommend prompt dermatologic assessment. Do not test it with abrasion or promise that pigment inhibitors will make it disappear. The appropriate action follows the reported evolution and symptoms, without the esthetician needing to name the cancer.

For the exam, distinguish melanin physiology from disease diagnosis and cosmetic product selection. Melanocytes synthesize pigment and transfer melanosomes to keratinocytes, but a visible patch does not reveal the exact number of cells, enzyme activity, or tissue depth. Medical evaluation and lawful cosmetic planning remain separate decisions.

Sources and current rules

FDA OTC hydroquinone warning; AAD skin-cancer recognition. Checked October 7, 2026.